文献速递银屑病与炎症性皮肤病

阿普米司特治疗轻中度斑块状银屑病的3期随机对照试验

Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2021-07-31

第16周时,阿普米司特组达到静态医生总体评估(sPGA)0或1且改善≥2分的比例显著高于安慰剂组(21.6% vs 4.1%,P < .0001),所有次要终点均达标。安全性特征与既往研究一致。

要点

  • 阿普米司特30 mg每日两次在第16周sPGA应答率显著优于安慰剂(21.6% vs 4.1%)。
  • 所有次要终点均达标,包括BSA-75、BSA≤3%、瘙痒NRS改善≥4分等。
  • 最常见不良事件(≥5%)为腹泻、头痛、恶心、鼻咽炎和上呼吸道感染。

核心结论

  • 阿普米司特对轻中度斑块状银屑病具有疗效,且安全性与此前已知的安全性特征一致。

主要发现

  • 第16周sPGA 0或1且改善≥2分的应答率:阿普米司特组21.6%,安慰剂组4.1%(P < .0001)。
  • BSA-75应答率:阿普米司特组33.0%,安慰剂组7.4%。
  • BSA≤3%比例:阿普米司特组61.0%,安慰剂组22.9%。
  • 全身瘙痒NRS改善≥4分比例:阿普米司特组43.2%,安慰剂组18.6%。
  • 头皮sPGA 0或1且改善≥2分比例:阿普米司特组44.0%,安慰剂组16.6%。

关键数值与推荐

  • 主要终点为第16周达到sPGA 0(清除)或1(几乎清除)且较基线改善≥2分。
  • 次要终点包括BSA-75、BSA≤3%、全身瘙痒NRS改善≥4分、头皮sPGA 0或1且改善≥2分,以及BSA、PASI和DLQI较基线的变化(所有P < .0001)。

临床怎么用

  • 对于外用治疗控制不佳或不耐受的轻中度斑块状银屑病成人患者,阿普米司特30 mg每日两次可作为系统治疗选择之一。
  • 治疗期间需关注腹泻、头痛、恶心、鼻咽炎和上呼吸道感染等常见不良事件。

局限性

  • 研究缺乏活性对照臂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment. OBJECTIVE: To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis. METHODS: Phase 3, double-blind, placebo-controlled study in adults with mild-to-moderate psoriasis inadequately controlled or intolerant to ≥ 1 topical psoriasis therapy (NCT03721172). The primary endpoint was the achievement of static Physician Global Assessment score of 0 (clear) or 1 (almost clear) and ≥ 2-point reduction at week 16. RESULTS: Five hundred ninety-five patients were randomized (apremilast: 297; placebo: 298). The primary endpoint was met, with a significantly greater static Physician Global Assessment response rate observed at week 16 in the apremilast group compared with the placebo group (21.6% vs 4.1%; P < .0001). All secondary endpoints were met with the achievement of body surface area-75 (33.0% vs 7.4%), body surface area ≤ 3% (61.0% vs 22.9%), ≥ 4-point reduction in Whole Body Itch Numeric Rating Scale (43.2% vs 18.6%), Scalp Physician Global Assessment 0 or 1 and ≥ 2-point reduction (44.0% vs 16.6 %), and changes from baseline in body surface area, Psoriasis Area and Severity Index, and Dermatology Life Quality Index (all P < .0001). The most commonly reported adverse events (≥ 5%) with apremilast were diarrhea, headache, nausea, nasopharyngitis, and upper respiratory tract infection, consistent with prior studies. LIMITATIONS: The study lacked an active-comparator arm. CONCLUSION: Apremilast demonstrated efficacy in mild-to-moderate psoriasis and safety consistent with the established safety profile of apremilast.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Stein Gold L, Papp K, Pariser D, et al. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2021. PMID: 34343599. doi:10.1016/j.jaad.2021.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。